Skip to main content
. Author manuscript; available in PMC: 2018 Nov 21.
Published in final edited form as: Mol Biosyst. 2017 Nov 21;13(12):2509–2520. doi: 10.1039/c7mb00391a

Fig. 11. Hypothetical model.

Fig. 11

Optimized AlphaLISA screen for PRMT5 inhibitors identified and confirmed P1608K04 and P1618J22 as two top hits. This inhibitory effect could partly be via inhibiting PRMT5-mediated NF-κB methylation and subsequent activation, resulting in decreased cancer associated target gene expression. This process would ultimately lead to the alleviation of cancer phenotype.